Diligence memo · auto-generated · as of July 2, 2026
Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals Plc looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Biodexa Pharmaceuticals Plc operates in Pharmaceuticals, based in CARDIFF.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Biodexa Pharmaceuticals Plc has raised $27M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $6.8M on 2023-12-21.
Most recent recorded round closed around 2024-07-19.
Valuation (modeled)modeled
Provath models Biodexa Pharmaceuticals Plc at approximately $25M (range $5.7M–$54M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.77× the median modeled value of Series A Pharmaceuticals companies in 2022–2024 (64 peers) — value vs value, same stage and era. Within the normal band (77% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 11 months.
Last raise 23 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round was 1.4× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 71% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 31% of those peers.
Closest niche peers: Hallux, Inc., Enalare Therapeutics Inc., Silver Creek Pharmaceuticals, Inc., NQ PE Project Stingray Parent, L.P., Acta Pharmaceuticals, Inc..
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.